Western Pacific Region Index Medicus

A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignancies.

Author: Lijun ZHAO ¹ ; Shuhong LI ¹ ; Xiaoyi WEI ¹ ; Xuexiu QI ¹ ; Qiaoru GUO ¹ ; Licai SHI ¹ ; Ji-Shuai ZHANG ² ; Jun LI ³ ; Ze-Lin LIU ⁴ ; Zhi GUO ⁴ ; Hongyu ZHANG ⁵ ; Jia FENG ⁵ ; Yuanyuan SHI ⁶ ; Suping ZHANG ⁷ ; Yu J CAO ¹
Author Information

1. State Key Laboratory of Chemical Oncogenomics, Shenzhen Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen 518055, China.
2. The Shenzhen Pregene Biopharma Company, Ltd., Shenzhen 518118, China.
3. Fundamenta Therapeutics Co., Ltd, Suzhou 215200, China.
4. Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, Nanshan Hospital, Shenzhen 518052, China.
5. Department of Hematology, Peking University Shenzhen Hospital, Shenzhen 518036, China.
6. Shenzhen Cell Valley Biomedical Co., LTD, Shenzhen 518118, China.
7. Shenzhen Key Laboratory of Precision Medicine for Hematological Malignancies, Base for International Science and Technology Cooperation: Carson Cancer Stem Cell Vaccines R&D Center, International Cancer Center, Shenzhen University Medical School, Shenzhen 518055, China.
Publication Type:Journal Article
From: Protein & Cell 2025;16(3):227-231
CountryChina
Language:English